Denis Chem Lab

Denis Chem Lab Equity

The The Equity of Denis Chem Lab (537536.BO) as of Oct 22, 2026 is 915.73 M INR. In the previous year, The Equity was 851.04 M INR — a change of 7.60% (higher).

Equity

915.73 MINR

YoY

7.60%

Last updated:

In 2025, Denis Chem Lab's equity was 915.73 M INR, a 7.60% increase from the 851.04 M INR equity in the previous year.

The Denis Chem Lab Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
564.57 M INR
Jan 1, 2019
590.87 M INR
Jan 1, 2020
615.05 M INR
Jan 1, 2021
664.51 M INR
Jan 1, 2022
722.63 M INR
Jan 1, 2023
803.67 M INR
Jan 1, 2024
851.04 M INR
Jan 1, 2025
915.73 M INR
The Denis Chem Lab Equity history
YEAREquityYoY
915.73 MINR+7.60%
851.04 MINR+5.90%
803.67 MINR+11.21%
722.63 MINR+8.75%
664.51 MINR+8.04%
615.05 MINR+4.09%
590.87 MINR+4.66%
564.57 MINR+13.06%
499.34 MINR+67.24%
298.57 MINR+81.29%
164.70 MINR+74.10%
94.60 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Denis Chem Lab Stock analysis

What does Denis Chem Lab do? Denis Chem Lab Ltd. generates revenue through the manufacture and sale of transfusion solutions in bottles, including sterile intravenous injectables for human and veterinary use. The company offers a range of products such as carbohydrate solutions, sodium chloride solutions, potassium chloride solutions, and plasma volume expanders under its own brands. It also produces sterile intravenous injectables in volumes from 100 milliliters to 10 liters for direct sales to customers. Additionally, the firm manufactures contract products for multinational pharmaceutical companies, leveraging its facility for third-party production. The company's primary customers include healthcare providers and veterinary institutions that require sterile intravenous solutions. Its product portfolio targets both human and veterinary markets, with offerings like antibiotic solutions and dialysis solutions catering to specific medical needs. The firm's contract manufacturing services provide an additional revenue stream by supplying multinational pharmaceutical companies with custom-produced sterile injectables. Denis Chem Lab Ltd. focuses on manufacturing and selling its own branded products, such as carbohydrate in sodium chloride solutions and multi electrolyte solutions, while also engaging in contract manufacturing for multinational pharmaceutical companies. The company's production capabilities span from small-volume solutions to large 10-liter bottles, ensuring versatility in meeting diverse customer demands across healthcare and veterinary sectors. Denis Chem Lab is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Denis Chem Lab's Equity

Denis Chem Lab's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Denis Chem Lab's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Denis Chem Lab's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Denis Chem Lab's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Denis Chem Lab’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Denis Chem Lab stock

The Equity of Denis Chem Lab is 915.73 M INR in 2025.

The Equity of Denis Chem Lab changed from 851.04 M INR to 915.73 M INR, representing a 7.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Denis Chem Lab since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Denis Chem Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Denis Chem Lab

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Denis Chem Lab